Production & Sales

Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.

Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada

Puma Biotechnology has entered into an exclusive license agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.

Eusa Pharma acquires iMCD treatment Sylvant for $115m

Biopharmaceutical firm Eusa Pharma has purchased worldwide rights of Sylvant (siltuximab) from Janssen Sciences Ireland for $115m.

Takeda completes $62bn acquisition of Irish biotech firm Shire

Japan-based Takeda Pharmaceutical has completed its previously announced $62bn acquisition of Irish rare disease biotech company Shire.

Lilly to acquire Loxo Oncology for $8bn

Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.

Catalent to invest $200m in biologics business

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.

Bristol-Myers Squibb to acquire Celgene for $74bn

Pharma giant Bristol-Myers Squibb has agreed to acquire US biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.

Nuvo Pharmaceuticals completes acquisition of revenue-generating products from Aralez

Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.

Portola secures FDA approval for Andexxa generation 2 manufacturing process

The US Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for the manufacturing process of second generation Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].